Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

10 sept. 2014 08h08 HE | Source: Sonoma Pharmaceuticals, Inc.

Oculus Innovative Sciences Introduces Microcyn(R)-Based Over-the-Counter Advanced Scar Management Hydrogel in United States

PETALUMA, Calif., Sept. 10, 2014 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a global healthcare company that designs, manufactures and markets prescription and...
07 août 2014 16h05 HE | Source: Sonoma Pharmaceuticals, Inc.

Oculus Innovative Sciences Reports Revenues of $3.4 Million and Net Loss of $70,000 for First Quarter of Fiscal 2015

Net loss of $70,000, reduced $1.6 million from same period last year Oculus owns two million shares of Ruthigen (Nasdaq:RTGN) Net worth of $13.4 million, up $10.8 million from June 30,...
24 juil. 2014 08h08 HE | Source: Sonoma Pharmaceuticals, Inc.

Oculus Innovative Sciences Announces Fiscal First Quarter 2015 Financial Results and Conference Call

PETALUMA, Calif., July 24, 2014 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced that the financial results for its fiscal first quarter 2015, ended June 30, 2014,...
12 juin 2014 16h05 HE | Source: Sonoma Pharmaceuticals, Inc.

Oculus Innovative Sciences Reports Revenues of $2.9 Million and Net Income of $7.5 Million for Fourth Quarter of Fiscal 2014 Primarily Due to Accounting Treatment of Ruthigen IPO Transaction

Oculus' subsidiary, Ruthigen, completes IPO, raising net proceeds of approximately $15.5 million Oculus owns two million shares of Ruthigen (Nasdaq:RTGN) and net worth increased $8.0 million...
29 mai 2014 08h08 HE | Source: Sonoma Pharmaceuticals, Inc.

Oculus Innovative Sciences Announces Fiscal Fourth Quarter 2014 Financial Results and Conference Call

PETALUMA, Calif., May 29, 2014 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced that the financial results for its fiscal fourth quarter 2014, ended March 31, 2014,...
22 avr. 2014 08h08 HE | Source: Sonoma Pharmaceuticals, Inc.

Oculus Innovative Sciences' Partner, More Pharma, Launches Microcyn(R)-Based Oral and Throat Infection Treatment Product in Mexico

PETALUMA, Calif., April 22, 2014 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) a global healthcare company that designs, manufactures and markets prescription and non-prescription...
09 avr. 2014 08h08 HE | Source: Sonoma Pharmaceuticals, Inc.

Oculus Innovative Sciences Receives 'Strong Consensus' Rating for Use With Kinetic Concepts' Negative Pressure Wound Therapy With Instillation

First International Consensus Guidelines published in December 2013 issue of Journal of Plastic and Reconstructive Surgery Microcyn® Solution Only One of Two Irrigation Products...
02 avr. 2014 08h08 HE | Source: Sonoma Pharmaceuticals, Inc.

Oculus Innovative Sciences Announces Board of Directors Restructuring Following Ruthigen IPO

Board Committees Restructured Election of Lead Independent Director Changes to Corporate Governance and Compensation Practices First in a Series of Modifications Based Upon...
27 mars 2014 08h08 HE | Source: Sonoma Pharmaceuticals, Inc.

Oculus Innovative Sciences Announces Appointment of Sharon Barbari to Its Board of Directors

PETALUMA, Calif., March 27, 2014 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced the appointment of Sharon Barbari to its board of directors, effective March 26,...
27 févr. 2014 08h08 HE | Source: Sonoma Pharmaceuticals, Inc.

Oculus Innovative Sciences Announces Appointment of Russell Harrison to Board of Directors

PETALUMA, Calif., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced the appointment of Russell ("Russ") Harrison to its board of directors, effective...

Page précédente

Page suivante